INVESTOR PRESENTATION FY26 Q2 November 2025 Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "in ...

Financial Performance - Assurant's YTD 2025 adjusted EBITDA, excluding catastrophes, increased by 13% compared to the prior year period[11] - Assurant's YTD 2025 adjusted EPS, excluding catastrophes, increased by 15% compared to the prior year period[11] - Assurant generated $487 million in cash YTD 2025[11] - Assurant returned $331 million to shareholders YTD 2025, including share repurchases and common stock dividends[11] - Assurant Q3 2025 adjusted EBITDA, excluding catastrophes, increased by 13% to $434 million, compared to $385 million in Q3 2024[41] - Assurant Q3 2025 adjusted EPS, excluding catastrophes, increased by 13% to $576 per share, compared to $508 per share in Q3 2024[41] Segment Performance - Global Lifestyle adjusted EBITDA increased by 6% on a constant currency basis YTD 2025[20] - Global Housing adjusted EBITDA, excluding catastrophes, increased by 21% YTD 2025, reaching $773 million compared to $641 million in the prior year period[22, 25] - Global Housing combined ratio for YTD 2025 was 78%, or 83% excluding prior year development[27] Outlook and Capital Allocation - Assurant is increasing its 2025 enterprise outlook to low double-digit growth in adjusted EPS and approaching 10% growth in adjusted EBITDA, both excluding catastrophes[13] - Assurant repurchased $81 million in shares in Q3 2025, with an additional $27 million repurchased between October 1 and October 31[42]

Q3 2025 Financial Results November 5, 2025 Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the deliv ...

D 2025 Earnings – Third Quarter November 5, 2025 2025 | Q3 Earnings Notices and Disclaimers Forward-Looking Statements. This presentation contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2025 full year and fourth quarter guidance, long-term expectations, our expectations regarding debt levels, and expectations regarding our industry and our operations, performance a ...

Adynatrace in addition to discusion financial measures measared in accordance with GAP, this presentation contains certain non-BAP financial measures as defined by Roudation G-inqual non-6AP operating marin), non-64AP net income, non-6AP netinqome per diluted share, free cash flow (FET), FE E margin, roe-tax FEF, and gre-lax FEF, marqin. Né-also use or eaminos releases, conference cally, other siller presentations and webcasts, Ne use these non-64AP intancial measures for financial meling urroses, and as a ...

3rd Quarter 2025 Financial Results November 5th, 2025 3rd Quarter 2025 Financial Results 2 Hippo-at- a-glance Technology native, multi-line carrier platform Scalable and efficient capital structure Market Leader in the New Home Builder Channel Disclaimers Certain statements included in this presentation that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements ge ...

November 5, 2025 Golar LNG Limited 2025 I Forward looking statements This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended) which reflects management's current expectations, estimates and projections about its operations. All statements, other than statements of historical facts, that address activities and events that will, should, could or may occur in the future are forward-looking statements. Words such as "if," "subject to," ...

Novo Nordisk (NYSE:NVO) Q3 2025 Earnings Call November 05, 2025 07:00 AM ET Speaker5Good day and thank you for standing by. Welcome to the Q3 2025 Novo Nordisk earnings conference call. At this time all participants are in a listen only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you will need to press star one and one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question ...

Third Quarter 2025 Earnings NOVEMBER 5, 2025 Safe Harbor / Non-GAAP Financial Disclosures Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our business strategy, plans and objectives and our expected or contemplated future operations, results, financial condition, beliefs and intentions. In addition, any statements ...

Nordea Bank (OTCPK:NBNK.F) 2025 Capital Markets Day November 05, 2025 07:00 AM ET Speaker0Good afternoon, everyone, and welcome to Nordea's 2025 Capital Markets Day. I'm Ilkka Ottola, Head of Investor Relations, and I'll be your moderator for the day. Today, we'll dive into the details behind our 2030 strategy with updated priorities and financial targets. We are excited to have the opportunity to talk about how we will take Nordea to the next level and create shareholder value. Let me briefly go through th ...